Longevity Startup Doses First Human

A longevity startup has administered its experimental ER-100 treatment to its first human participant. This groundbreaking trial aims to reverse age-related vision loss by targeting cellular aging. The technology claims to rejuvenate cells, and this marks the first time it has been tested in a human subject. The company is hopeful this will lead to new therapies for degenerative eye conditions and potentially other age-related diseases.